2 results match your criteria: "Northern Light Cancer Center[Affiliation]"
Article Synopsis
- The study evaluates the effectiveness of targeted agents, specifically pertuzumab plus trastuzumab, in patients with advanced biliary tract cancer (BTC) who have specific genomic alterations.
- Out of 29 enrolled patients, the treatment showed a 40% disease control rate, with some experiencing significant responses, indicating potential benefits of this combination therapy.
- Although the treatment was generally well-received, a few patients reported notable adverse events, highlighting the importance of monitoring safety alongside treatment efficacy.
We report here a rare case of atypical posterior reversible encephalopathy syndrome (PRES) due to oral tyrosine kinase inhibitor cabozantinib. No case reports of such have been found in our literature search. The patient, a 70-year-old female with metastatic renal cell cancer on oral tyrosine kinase inhibitor cabozantinib, was brought into the emergency room because of confusion and seizures, found to have elevated blood pressure and atypical MRI findings consistent with PRES due to cabozantinib.
View Article and Find Full Text PDF